• Image of Atripla medication Image of Atripla medication
    • EFAVIRENZ-EMTRIC-TENOFOV DISOP (Generic for ATRIPLA)

    • QTY 30
    • 600-200MG
    • Tablet
    • Near  77381

EFAVIRENZ; EMTRICITABINE; TENOFOVIR (e fa VEER ens; em tri SIT uh bean; te NOE fo veer) helps manage the symptoms of HIV infection. It works by limiting the spread of HIV in the body. It is a combination of three antiretroviral medications. This medication is not a cure for HIV or AIDS and it may still be possible to spread HIV to others while taking it. It does not prevent other sexually transmitted infections (STIs).


What does EFAVIRENZ-EMTRIC-TENOFOV DISOP (Generic for ATRIPLA) look like?

View images of EFAVIRENZ-EMTRIC-TENOFOV DISOP (Generic for ATRIPLA) and identify pills by imprint, color or shape. If you need to save money on your EFAVIRENZ-EMTRIC-TENOFOV DISOP (Generic for ATRIPLA), compare our prices. Our prescription savings may even be lower than your insurance copay!

Note: Multiple images may be displayed for medicines available in different strengths, sold under different brand names, or manufactured by different pharmaceutical companies.

Enfav/Emtric/Tenofovir Tablet
Enfav/Emtric/Tenofovir Tablet

Strength: 600-200MG

Pill Imprint: C210

Color: pink

Shape: oblong

Enfav/Emtric/Tenofovir Tablet
Enfav/Emtric/Tenofovir Tablet

Strength: 600-200MG

Pill Imprint: I48

Color: white

Shape: oval

Enfav/Emtric/Tenofovir Tablet
Enfav/Emtric/Tenofovir Tablet

Strength: 600-200MG

Pill Imprint: LA36

Color: pink

Shape: oblong

Enfav/Emtric/Tenofovir Tablet
Enfav/Emtric/Tenofovir Tablet

Strength: 600-200MG

Pill Imprint:

Color:

Shape:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.